KLF6 function is abrogated in human cancers owing to increased AS that yields a dominant-negative isoform, KLF6 SV1, which antagonizes full-length KLF6-mediated growth suppression [111], presumably by promoting KLF6 degradation [112]. This evidence concerns the gene KLF6 and cancer.